Responses were seen mainly in PD-L1+ tumors , and remarkably, in the bladder cancer cohort all patients with TPS ≥ 5 in baseline tumor biopsy experienced a PR or CR. Depth and durability of responses was significant, with several responses ongoing at 1yr and beyond, despite all patients being in last-line situation...Visugromab in combination with nivolumab demonstrated excellent safety and promising antitumoral activity in last-line, and by stringent criteria anti-PD1/PD-L1 relapsed/refractory solid tumor patients.